Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01045993 · ClinicalTrials.gov registry record · NA
A Study To Evaluate Methods To Evaluate Back Pain
A NA study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- NA
- Development phase
- 61
- Enrollment target
NCT01045993: Completed NA study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
NCT01045993 is a NA study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 61 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01045993, a NA study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- NA
- Development phase
- 61 participants
- Enrollment target
Study Summary
The study is designed to assess methods used in clinical research.
Primary Outcome
"First perceptible relief" defined as the elapsed time from wrap application or oral treatment until the participant depressed the first stopwatch labeled "first perceptible relief" (any pain relieving effect), provided the participant also depressed the second stopwatch labeled "meaningful relief" (meaningful to participant) by the end of the scheduled in-patient evaluation (4 hours / 240 minutes). If the confirmation was not achieved, the participant was censored at the time when the first sto
Interventions
- DRUG Placebo
- DEVICE Sham Device
- DEVICE Heat Device
- DRUG marketed analgesic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2010-02 |
| Est. Completion | 2010-07 |
| Phase | NA |
What the finished NCT01045993 record still lists
NCT01045993 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01045993 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01045993 about?
NCT01045993 is a clinical study titled "A Study To Evaluate Methods To Evaluate Back Pain". The study is designed to assess methods used in clinical research.
What is the current status of trial NCT01045993?
This trial is currently completed. It is a NA study. The enrollment target is 61 participants. The study started on 2010-02. Estimated completion is 2010-07.
What interventions are being tested in trial NCT01045993?
The interventions under investigation include: Placebo (DRUG), Sham Device (DEVICE), Heat Device (DEVICE), marketed analgesic (DRUG).
Who is sponsoring clinical trial NCT01045993?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01045993's enrollment target sits among peer trials
61 1164th of 2000 higher than 837 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia